法信諾生醫股份有限公司
Update：2025/06/30
Industries
Main Industry
Health Care
Main Product/Service
1. COVID-19 Vaccine (V-CO)
2. Nucleic acid medicine- V-ADmir
3. Brain Delivery Platform- VBT
2. Nucleic acid medicine- V-ADmir
3. Brain Delivery Platform- VBT
Founded Year
2020
Unified Business No.
83702127
Status
Active
Number of Employees
0
Total Paid-in
Capital
36,500,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Founded in July 2020, Vacino Biotech is committed to the development of novel nucleic acid drugs and universal vaccines. With the self-developed next-generation vaccine design SED technology, we have invested in the development of COVID-19 T-cell vaccine products to solve the situation of rapid mutation of the new coronavirus variants. In addition, it has invested in the development of nucleic acid drugs for the treatment of Alzheimer's disease and a cutting-edge efficient brain delivery technology to increase the content of brain treatment drugs and prevent the occurrence of diseases at an early stage.
